Effectiveness and tolerance of antituberculosis treatment regimens without isoniazid and rifampicin: Analysis of 85 cases

Archivos de Bronconeumologia

Volumn 44, Issue 9, 2008, Pages 478-483

  Tost, José R ^a,b   Vidal, Rafael ^b   Maldonado, José ^c   Caylà, Joan A ^d  

^a HOSPITAL DE TERRASSA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Serveis Clinics   (Spain)

^d AGÈNCIA DE SALUT PÚBLICA DE BARCELONA   (Spain)

Author keywords

Antituberculosis drugs; Drug resistance; Drug toxicity; Mycobacterium tuberculosis; Tuberculosis

Indexed keywords

CYCLOSERINE; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE TOXICITY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; TREATMENT RESPONSE; TUBERCULOSIS; LUNG TUBERCULOSIS; MIDDLE AGED; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIFAMPIN; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 55049102658     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1157/13126092     Document Type: Article

References (25)

1. Fox W. Whither short-course chemotherapy? Br J Dis Chest. 1981;75:331-57.
2. World Health Organization. Treatment of tuberculosis. Guidelines for National Programmes. WHO Report 2003. Document WHO/CDS/TB 2003/313. Geneva: World Health Organization; 2003.
3. Caylà JA, Caminero JA, Rey R, Lara N, Vallés X, Galdós-Tangüis H. Working Group on Completion of Tuberculosis Treatment in Spain. Current status of treatment completion and fatality among tuberculosis patients in Spain. Int J Tuberc Lung Dis. 2004;8:458-64.
4. Díez M, Hernández JA, Caloto T, Castells C, Domínguez A, García AM, et al. Resultados del tratamiento antituberculoso en seis comunidades autónomas españolas. Med Clin (Barc). 2001;117:574-80.
5. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603-62.
6. Faustini A, Hall AJ, Perucci CA. Tuberculosis treatment outcomes in Europe: a systematic review. Eur Respir J. 2005;26:503-10.
7. Chan ED, Laurel V, Strand MJ, Chan MJ, Huynh ML, Goble M, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2004;169:1103-9.
8. Migliori GB, Besozzi G, Girardi E, Kliiman K, Lange C, Toungoussova OS, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J. 2007; 30: 623-6.
9. Vidal R, Rey R, Espinar A, de March P, Melero C, Pina JM, et al. Tratamiento y retratamiento de la tuberculosis. Arch Bronconeumol. 1996;32:463-74.
10. Schluger NW. The impact of drug resistance on the global tuberculosis epidemic. Int J Tuberc Lung Dis. 2000;4 (2 Suppl 1):S71-5.
11. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis. 1986;133:423-30.
12. Bobrowitz ID. Ethambutol-isoniazid vs. streptomycin-ethambutol-isoniazid in original treatment of cavitary tuberculosis. Am Rev Respir Dis. 1974;109:548-53.
13. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA. 2000;283:2537-45.
14. Tahao lu K, Törün T, Sevim T, Ataç G, Kir A, Karasulu L, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med. 2001;345:170-4.
15. Caminero JA. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis. 2006;10:829-37.
16. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/ 2006.361. Geneva: WHO;2006.
17. Caminero JA. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Respir J. 2005;25:928-36.
18. Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis. 1998;2:877-84.
19. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999;281:1014-8.
20. Tost J, Vidal R, Caylà J, Broquetas J, Díaz Cabanela D, Jiménez A. Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis. 2005;9:534-40.
21. Vidal Pla R, de Gracia X, Gallego B, Algueró C, Bravo C. Hepatotoxicidad del tratamiento de la tuberculosis. Med Clin (Barc). 1991;97:481-5.
22. Durand F, Bernuau J, Pessayre D, Samuel D, Belaiche J, Degott C, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology. 1995;21:929-32.
23. Jiménez MA. Prevenció i control de la tuberculosi en els immigrants. Annals de Medicina. 2006;89:5-7.
24. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009-21.
25. Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC, et al. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med. 1991;324:289-94.